Gene therapy aims to free patients from daily steroids for rare adrenal disorder
NCT ID NCT04783181
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a gene therapy called BBP-631 for classic congenital adrenal hyperplasia (CAH), a genetic condition that forces patients to take daily steroids. The therapy uses a harmless virus to deliver a working copy of the faulty gene. Only 8 adults are enrolled to check safety and whether it can lower stress hormones and raise natural cortisol levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BBP-631 (a gene therapy using a harmless virus to deliver a working copy of the CYP21A2 gene)
What this could lead to
If successful, this could reduce or eliminate the need for daily steroid medication in people with classic congenital adrenal hyperplasia.
What could go wrong
This is a very early, small trial (8 people) testing safety first. Gene therapy is complex and may not work as hoped, and there are risks like immune reactions or liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Lucas Research, Inc.
Morehead City, North Carolina, 28557, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892-1932, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States